Why the study?
Is hepatitis C virus infection associated with a higher prevalence of dilated cardiomyopathy in patients with end-stage heart failure?
Population
752 consecutive patients with end-stage heart failure who entered the waiting list for cardiac…
Comparison
HCV infection (assessed by anti-HCV antibodies) vs Patients with end-stage heart failure without…
Design
Cross-sectional
Authors
Loading...
No HCV-DCM link in end-stage HF; leaves open its pathogenic role and should not change practice.
Is hepatitis C virus infection associated with a higher prevalence of dilated cardiomyopathy in patients with end-stage heart failure?
HCV infection does not appear to have a primary role in the pathogenesis of dilated cardiomyopathy in Italian patients with end-stage heart failure, challenging previous hypotheses.
Prati et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: